Medicine and Dentistry
Patient
100%
Rituximab
50%
Personalized Medicine
50%
Diffuse Large B-Cell Lymphoma
50%
Hospital
50%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
50%
Hematological Cancer
50%
Development
50%
Prognosis
50%
Neoplasm
20%
Malignant Neoplasm
20%
Analysis
20%
Gene
14%
Exome
10%
Hematologic Malignancy
10%
Diseases
10%
Microsatellite Instability
10%
RNA
10%
Nucleotide
10%
Progressive Disease
10%
Accuracy
10%
Patient Referral
10%
Relapse
10%
Medicine
10%
Therapeutic Procedure
8%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
50%
Diffuse Large B Cell Lymphoma
50%
Malignant Neoplasm
50%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
50%
Prognosis
50%
Prospective Study
30%
Neoplasm
20%
Diseases
20%
Hematologic Malignancy
10%
DNA
10%
RNA
10%
Relapse
10%
Biochemistry, Genetics and Molecular Biology
Accuracy
50%
Development
50%
Electric Potential
20%
Microsatellite Instability
10%
Sample
10%
RNA
10%
Fusion Transcript
10%
DNA
10%
Relapse
10%
Solid
10%
Sequencing
10%
Exome
10%
Mutated Genes
10%
Nucleotide
10%
